Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Fig. 2

Interaction between tumor metabolism and the mTOR signaling pathway. The mTOR pathway is closely related to tumor metabolism. Pathway 1: In bladder cancer, down-regulation of PKM2 expression reduces SREBP-1 expression through inactivated AKT/TSC/Rehb/mTORC1 pathway. The down-regulation of SREBP-1c inhibits FA generation by inhibiting FASN transcription, leading to the inhibition of tumor growth.). Pathway 2: Up-regulation of TEF in tumors activates the Ras/Erk/TSC/Rehb/mTORC1 pathway. Activation of this pathway will promote the uptake of nutrients by tumor cells to meet the needs of the rapid growth of tumors. Pathway 3: HCC can increase sphingomyelin and cardiolipin production by activating mTORC2. Large amounts of sphingomyelin and cardiolipin are used to assemble cell membranes, which also meet the needs of rapid tumor proliferation. Pathway 4: The accumulation of BCAA can promote the occurrence and development of tumors by activating mTORC1. Pathway 5: A2aR, which is highly expressed in gastric cancer, binds adenosine to activate the PI3K/AKT/mTORC1 pathway. Pathway 6: In breast cancer, FFAs promotes tumor proliferation and metastasis by activating the PI3K/AKT/mTORC1 pathway. Pathway 7: The PI3K/AKT/mTORC1/SREBP pathway promotes breast cancer proliferation by inducing new lipid synthesis

Back to article page